• Japanese
  • Korean
  • Chinese
Cover Image

Biosimilars: Global Regulatory Update

Abstract

Introduction

After consultation with industry, the FDA published draft biosimilars guidelines in February 2012. Although details are lacking in a number of areas such as interchangeability, the guidance sets out the agency's broad views and gives developers greater certainty for the initiation of development programs.

Features and benefits

  • Insight into the key biosimilar regulatory developments globally
  • Assessment of the key strategies incorporated by players as a response to these changes in biosimilar regulation

Highlights

The FDA published draft biosimilars guidelines in February 2012.

In the EU, the EMA has published guidance for the development of interferon beta biosimilars.

In order to meet physician and patient demands for more complex drugs and reduce the financial burden on payers, the Iranian government is keen to promote the Iranian biosimilars industry.

Your key questions answered

  • Evaluate the evolving regulatory environment around the world and how this impacts biosimilar market access and uptake.
  • Gain insight into the strategies employed by payers and pharmaceutical companies as a response to these changes in the regulatory environment.

Table of Contents

ABOUT THIS REPORT

  • PharmaVitae Explorer database

EXECUTIVE SUMMARY

  • Introduction
  • Key findings
    • Other US biosimilars regulatory issues
    • EU biosimilar regulatory developments
    • Rest of world biosimilar regulatory developments
    • Country-specific biosimilar definitions
  • Biosimilars approval pathways

BIOSIMILAR REGULATORY UPDATES

  • FDA biosimilar development guidelines outline the agency's current thinking
    • (Untitled sub-section)
    • Reference product considerations
    • Biosimilar design and manufacturing
    • Preclinical studies
    • Clinical studies
    • Indication extrapolation
    • Interchangeability requirements
    • Post-marketing requirements
  • PDUFA V to be approved by September 2012
    • The FDA aims to review biosimilar applications within 10 months
  • EU issues new guidelines
    • EU issues draft interferon beta guidelines
    • German reference price cuts to affect biosimilar epoetins
    • Belgium to set biosimilar target
  • Emerging markets

APPENDIX

  • References
    • Datamonitor reports
  • Exchange rates

TABLES

  • Table: Biosimilars approval pathways
  • Table: Comparison of biosimilar guidelines across major markets, 2012
  • Table: Comparison of biosimilar guidelines across major markets, 2012
  • Table: EMA H1 2012 biosimilars guidance timetable
  • Table: Pipeline and marketed biosimilar/copy-biologic interferon beta drugs
  • Table: Germany - biosimilar epoetin products marketed in Germany, 2012
  • Table: Exchange rates, 2011

FIGURES

  • Figure: The PharmaVitae Explorer
Show More
RELATED REPORTS
* PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines
  • Published:
  • Aug 01, 2014
  • USD 2620
  • 183 Pages

* Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
  • Published:
  • Jul 01, 2014
  • USD 4515
  • 184 Pages

* PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market
  • Published:
  • Jun 30, 2014
  • USD 2995
  • 173 Pages

* The Future of Biosimilars: mapping critical uncertainties and the impact of future events
  • Published:
  • May 05, 2014
  • USD 1950
  • 120 Pages

* Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024
  • Published:
  • May 01, 2014
  • USD 2986
  • 263 Pages

* Biosimilar Index: Tracking the Biosimilar Development Landscape
  • Published:
  • Apr 02, 2014
  • USD 4995
  • Database + 135 Slides

* Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014
  • Published:
  • Mar 12, 2014
  • USD 1523
  • 386 Pages

* Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
  • Published:
  • Feb 28, 2014
  • USD 419
  • 70 Pages

* Emergence Of Biogenerics Era In Japan: It's Time to Welcome antibody Biosimilars of Foreign Origins Soon!
  • Published:
  • Feb 25, 2014
  • USD 2500
  • 31 Pages

* Commercial Potential of the Forthcoming US Biosimilars Market
  • Published:
  • Feb 21, 2014
  • USD 5000
  • 156 Pages

Browse more Biosimilar Market Research Reports

Pricing
Get Notified
Email me when related reports are published